<DOC>
	<DOCNO>NCT02616445</DOCNO>
	<brief_summary>The purpose study determine whether drug UE2343 , potential treatment Alzheimer 's Disease ( AD ) , effective assess safety , tolerability , pharmacokinetics pharmacodynamics Multiple Ascending Dose Study . Protocol amendment study examine food effect determine drug penetrate Blood-Brain Barrier .</brief_summary>
	<brief_title>Phase I MAD , Fed-Fasted , CSF Study UE2343 Healthy Subjects</brief_title>
	<detailed_description>Part 1 study double-blind , randomise , placebo-controlled , multiple ascend dose study assess safety , tolerability , PK PD healthy participant dose twice daily level 10 , 20 35mg 10 days.This part study recruit 3 group 8 participant . Part 2 cross-over study assess effect food PK UE2343 healthy participant dose two single dos level decide Part 1 . This part study recruit total 12 participant . Part 3 seek determine PK UE2343 CSF healthy participant dose twice daily 4 day dose level determine Part 1 2 . This part study recruit 4 participant . Strategies ensure adherence study include requirement participant remain clinical research facility duration participation study ; drug accountability check ( i.e . reconciliation use unused capsule ) independent clinical research associate ; administration capsule participant member study site team .</detailed_description>
	<criteria>Willing use specify contraception BMI within specify range No clinically significant abnormality result laboratory evaluation Screening Day 1 . Abnormal medical history , include history dementia No significant allergic reaction No prior drug alcohol abuse Use regular prescribe medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>